Gastroenterology
Volume 138, Issue 2 , Pages 503-512.e1, February 2010

Peginterferon Alfa-2a/Ribavirin for 48 or 72 Weeks in Hepatitis C Genotypes 1 and 4 Patients With Slow Virologic Response

  • Peter Ferenci

      Affiliations

    • Department of Internal Medicine III, Medical University, Vienna, Austria
    • Universitätsklinik für Innere Medizin III, AKH Wien, Vienna, Austria
    • Corresponding Author InformationReprint requests Address requests for reprints to: Professor Dr Peter Ferenci, Universitätsklinik für Innere Medizin III, AKH Wien, Waehringer Guertel 18-20, A 1090 Wien, Austria. fax: (43) 1-40400-4735
    • ,
  • Hermann Laferl

      Affiliations

    • Department of Internal Medicine, Kaiser-Franz-Josef-Spital, Vienna, Austria
    • ,
  • Thomas–Matthias Scherzer

      Affiliations

    • Department of Internal Medicine III, Medical University, Vienna, Austria
    • ,
  • Andreas Maieron

      Affiliations

    • Department of Internal Medicine, Elisabethinen Hospital, Linz, Austria
    • ,
  • Harald Hofer

      Affiliations

    • Department of Internal Medicine III, Medical University, Vienna, Austria
    • ,
  • Rudolf Stauber

      Affiliations

    • Department of Internal Medicine, Medical University, Graz, Austria
    • ,
  • Michael Gschwantler

      Affiliations

    • Department of Internal Medicine IV, Wilhelminenspital, Vienna, Austria
    • ,
  • Harald Brunner

      Affiliations

    • Department of Internal Medicine I, Hospital Hietzing, Wien, Austria
    • ,
  • Christoph Wenisch

      Affiliations

    • Department of Internal Medicine, Kaiser-Franz-Josef-Spital, Vienna, Austria
    • ,
  • Martin Bischof

      Affiliations

    • Department of Internal Medicine IV, Rudolfshospital, Vienna, Austria
    • ,
  • Michael Strasser

      Affiliations

    • Department of Internal Medicine I, Paracelsus Private University, Salzburg, Austria
    • ,
  • Christian Datz

      Affiliations

    • Krankenhaus, Oberndorf, Austria
    • ,
  • Wolfgang Vogel

      Affiliations

    • Department of Gastroenterology and Hepatology, Medical University, Innsbruck, Austria
    • ,
  • Karin Löschenberger

      Affiliations

    • Roche Austria, Vienna, Austria
    • ,
  • Petra Steindl–Munda

      Affiliations

    • Department of Internal Medicine III, Medical University, Vienna, Austria
    • ,
  • Austrian Hepatitis Study Group

Received 9 August 2009; accepted 21 October 2009. published online 11 November 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Conflicts of interest These authors disclose the following: Peter Ferenci serves on advisory boards, is a speaker and investigator for, and also has received research grants from F. Hoffmann-La Roche; Michael Gschwantler, Wolfgang Vogel, Petra Steindl-Munda, and Rudolf Stauber serve as a speaker for F. Hoffmann-La Roche; and Karin Löschenberger is an employee of F. Hoffmann-La Roche. The remaining authors disclose no conflicts.

 Funding This study was made possible by an unrestricted grant by Roche Austria. Roche Austria had no role in the study design; in the collection, analysis, and interpretation of data; and in the decision to submit the report for publication. The Main Association (Hauptverband) of the Austrian Health Insurers paid for the study medication.

PII: S0016-5085(09)01961-1

doi:10.1053/j.gastro.2009.10.058

Gastroenterology
Volume 138, Issue 2 , Pages 503-512.e1, February 2010

Article Tools

* Image Usage & Resolution